Ligand Pharmaceuticals Incorporated
LGND
$210.99
$3.191.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -61.81% | 2,319.50% | 111.42% | -36.55% | -333.46% |
| Total Depreciation and Amortization | -10.30% | 13.12% | -2.58% | -3.69% | -4.08% |
| Total Amortization of Deferred Charges | 12.85% | 72.44% | -24.05% | -4.85% | 5.09% |
| Total Other Non-Cash Items | 83.20% | -1,320.72% | -35.47% | -65.90% | 43.55% |
| Change in Net Operating Assets | 187.51% | -72.01% | -19.41% | -144.54% | 62.93% |
| Cash from Operations | 250.76% | -17.15% | 162.09% | -189.37% | -22.06% |
| Capital Expenditure | 40.00% | 92.99% | 0.00% | 69.94% | -19.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.17% | -3,281.13% | -304.64% | 113.47% | 17.43% |
| Cash from Investing | 94.88% | -3,213.44% | -317.96% | 112.67% | 16.95% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 99.99% | -1,617,842.86% | 0.00% | -16.67% | 40.00% |
| Issuance of Common Stock | -63.88% | 212.44% | 95.14% | -81.19% | -59.50% |
| Repurchase of Common Stock | 97.74% | -10,395.86% | 98.37% | -359.48% | -1,448.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -101.18% | 658.22% | 9,829.58% | 39.83% | 43.81% |
| Cash from Financing | -97.97% | 2,631.88% | 415.88% | -123.28% | -62.98% |
| Foreign Exchange rate Adjustments | -47.50% | -117.45% | 116.64% | 168.35% | -510.61% |
| Miscellaneous Cash Flow Adjustments | -- | 202.85% | -3,411.54% | -- | -- |
| Net Change in Cash | -50.42% | 264.36% | 180.93% | -379.90% | -80.90% |